Despite aggressive treatment, vascular pythiosis has a mortality rate of 40%. This is due to delays in diagnosis and a lack of effective monitoring tools. To overcome this drawback, serum beta-d-glucan (BG) and -specific antibody (-Ab) were examined as potential monitoring markers in vascular pythiosis. A prospective cohort study of vascular pythiosis patients was carried out from January 2010 to July 2016. Clinical information and blood samples were collected and evaluated by the BG and -Ab assays. Linear mixed-effect models were used to compare BG and-Ab levels. The susceptibility test was performed with all isolates from culture-positive cases. A total of 50 patients were enrolled: 45 survived and 5 died during follow-up. The survivors had a significantly shorter time to medical care ( < 0.0001) and a significantly shorter waiting time to the first surgery ( < 0.0001). There were no differences in BG levels among the groups at diagnosis ( = 0.33); however, BG levels among survivors were significantly lower than those of the deceased group at 0.5 months ( < 0.0001) and became undetectable after 3 months. Survivors were able to maintain an enzyme-linked immunosorbent assay (ELISA) value (EV) of -Ab above 8, whereas the EV among deceased patients was less than 4. susceptibility results revealed no synergistic effects between itraconazole and terbinafine. This study showed that BG and -Ab are potentially valuable markers to monitor the disease after treatment initiation. An unchanged BG level at 2 weeks after surgery should prompt an evaluation for residual disease.